Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
Patients on Vafseo® (vadadustat) increased to approximately 11,500 at the end of Q3 2026 representing an increase of approximately 140% from the end of Q3 2025
Covered in this story
Call it yourself
No calls on $AKBA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Akebia Therapeutics Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.